ANGPTL4

Last updated
ANGPTL4
ANGPTL4.png
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases ANGPTL4 , ANGPTL2, ARP4, FIAF, HARP, HFARP, NL2, PGAR, TGQTL, UNQ171, pp1158, angiopoietin like 4
External IDs OMIM: 604774, 605910 MGI: 1888999 HomoloGene: 10755 GeneCards: ANGPTL4
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001039667
NM_016109
NM_139314

NM_020581

RefSeq (protein)

NP_001034756
NP_647475

NP_065606

Location (UCSC) Chr 19: 8.36 – 8.37 Mb Chr 17: 33.99 – 34 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Angiopoietin-like 4 is a protein that in humans is encoded by the ANGPTL4 gene. [5] [6] [7] Alternatively spliced transcript variants encoded with different isoforms have been described. This gene was previously referred to as ANGPTL2, HFARP, PGAR, or FIAF but has been renamed ANGPTL4.

Contents

This gene is induced under hypoxic (low oxygen) condition in various cell types and is the target of peroxisome proliferator-activated receptors. The encoded protein is a serum hormone directly involved in regulating lipid metabolism.

ANGPTL4 plays an important role in numerous cancers and is implicated in the metastatic process by modulating vascular permeability, cancer cell motility and invasiveness. [8] [9] [10]

Name

The former name, FIAF, stands for Fasting-Induced Adipose Factor.

Structure

This gene is a member of the angiopoietin-like gene family and encodes a glycosylated, secreted protein with a coiled-coil N-terminal domain and a fibrinogen-like C-terminal domain. [11]

Expression

In mice, the highest mRNA expression levels of ANGPTL4 are found in white and brown adipose tissue, followed by liver, kidney, muscle and intestinal tissues. Human ANGPTL4 is most highly expressed in the liver as a hepatokine.

Function

Picture depicts role of ANGPTL4 as endogenous inhibitor of lipoprotein lipase and its regulation by fatty acids via Peroxisome Proliferator Activated Receptors Overview ANGPTL4.png
Picture depicts role of ANGPTL4 as endogenous inhibitor of lipoprotein lipase and its regulation by fatty acids via Peroxisome Proliferator Activated Receptors

This gene is induced under hypoxic (low oxygen) condition in various cell types and is the target of peroxisome proliferator-activated receptors. The encoded protein is a serum hormone directly involved in regulating lipid metabolism. The native full length ANGPTL4 can form higher order structures via intermolecular disulfide bonds. The N-terminal region of ANGPTL4 (nANGPTL4) is responsible for its assembly. The full length ANGPTL4 undergoes proteolytic cleavage at the linker region, releasing nANGPTL4 and the monomeric C-terminal portion of ANGPTL4 (cANGPTL4). The nANGPTL4 and cANGPTL4 have different biological functions. [11] Monoclonal antibodies targeting the nANGPTL4 [12] and cANGPTL4 [13] have been developed to distinguish their functions.

Clinical significance

ANGPTL4 plays an important role in numerous cancers and is implicated in the metastatic process by modulating vascular permeability, cancer cell motility and invasiveness. [8] [9] [10] ANGPTL4 contributes to tumor growth and protects cells from anoikis, a form of programmed cell death induced when contact-dependent cells detach from the surrounding tissue matrix. [13] ANGPTL4 secreted from tumors can bind to integrins, activating downstream signaling and leading to the production of superoxide to promote tumorigenesis. [14] ANGPTL4 disrupts endothelial cell junctions by directly interacting with integrin, VE-cadherin and claudin-5 in a sequential manner to facilitate metastasis. [15] ANGPTL4, specifically the C-terminal fragment (cANGPTL4), is a key player that coordinates an increase in cellular energy flux crucial for epithelial-mesenchymal transition (EMT) via an ANGPTL4:YWHAG (14-3-3γ) signaling axis. [16] [17] The ANGPTL4:YWHAG signaling axis confers metabolic flexibility and enhances EMT competency through interaction with specific phosphorylation signals on target proteins. A direct consequence is that ANGPTL4 secures ample cellular energy to fuel multiple ABC transporters to confer EMT-mediated chemoresistance. [18]

ANGPTL4 functions as a matricellular protein [19] to facilitate skin wound healing. ANGPTL4-deficient mice exhibit delayed wound reepithelialization with impaired keratinocyte migration, angiogenesis and altered inflammatory response. [20] [21] ANGPTL4 induces nitric oxide production through an integrin/JAK/STAT3-mediated upregulation of iNOS expression in wound epithelia, and enhances angiogenesis to accelerate wound healing in diabetic mice. [22] ANGPTL4 induces a β-catenin-mediated upregulation of ID3 in fibroblasts to reduce scar collagen expression. [23] ANGPTL4 is capable of reversing the fibroblast-to-myofibroblast differentiation induced aligned electrospun fibrous substrates. [24] Cyclic stretching of human tendon fibroblasts stimulated the expression and release of ANGPTL4 protein via TGF-β and HIF-1α signalling, and the released ANGPTL4 was pro-angiogenic. [25] ANGPTL4 is also a potent angiogenic factor whose expression is up-regulated in hypoxic retinal Müller cells in vitro and the ischemic retina in vivo. The expression of ANGPTL4 was increased in the aqueous and vitreous of proliferative diabetic retinopathy patients and localized to areas of retinal neovascularization. [26]

ANGPTL4 has been established as a potent inhibitor of serum triglyceride (TG) clearance, causing elevation of serum TG levels via inhibition of the enzyme lipoprotein lipase (LPL). Biochemical studies indicate that ANGPTL4 disables LPL partly by dissociating the catalytically active LPL dimer into inactive LPL monomers. [27] However, evidence also suggests that ANGPTL4 functions as a conventional, non-competitive inhibitor that binds to LPL to prevent the hydrolysis of substrate as part of reversible mechanism. [28] As a consequence, ANGPTL4 knockout mice have reduced serum triglyceride levels, whereas the opposite is true for mice over-expressing ANGPTL4. ANGPTL4 suppresses foam cell formation to reduce atherosclerosis development. [29] The reduction in LPL activity in adipose tissue during fasting is likely caused by increased local production of ANGPTL4. In other tissues such as heart, production of ANGPTL4 is stimulated by fatty acids and may serve to protect cells against excess fat uptake. [30] ANGPTL4 is more highly induced in nonexercising muscle than in exercising human muscle during acute exercise. ANGPTL4 in nonexercising muscle presumably leads to reduced local uptake of plasma triglyceride-derived fatty acids and their sparing for use by exercising muscle. The induction of ANGPTL4 in exercising muscle likely is counteracted via AMP-activated protein kinase (AMPK)-mediated down-regulation, promoting the use of plasma triglycerides as fuel for active muscles. [31]

High-throughput RNA sequencing of lung tissue samples from the 1918 and 2009 influenza pandemic revealed that ANGPTL4 was one of the most significantly upregulated gene. [32] Murine influenza infection of the lungs stimulated the expression of ANGPTL4 via a STAT3-mediated mechanism. ANGPTL4 enhanced pulmonary tissue leakiness and exacerbated inflammation-induced lung damage. Influenza-infected ANGPTL4-knockout mice displayed diminished lung damage and recovered faster from the infection compared to wild-type mice. The treatment of infected mice with neutralizing anti-ANGPTL4 antibodies significantly accelerated pulmonary recovery and improved lung tissue integrity. [33] It was also shown that antibody treatment against ANGPTL4 reduces pulmonary edema and injury in secondary pneumococcal pneumonia. [34]

Related Research Articles

<span class="mw-page-title-main">Adipose tissue</span> Loose connective tissue composed mostly by adipocytes

Adipose tissue is a loose connective tissue composed mostly of adipocytes. It also contains the stromal vascular fraction (SVF) of cells including preadipocytes, fibroblasts, vascular endothelial cells and a variety of immune cells such as adipose tissue macrophages. Its main role is to store energy in the form of lipids, although it also cushions and insulates the body.

<span class="mw-page-title-main">Peroxisome proliferator-activated receptor</span> Group of nuclear receptor proteins

In the field of molecular biology, the peroxisome proliferator–activated receptors (PPARs) are a group of nuclear receptor proteins that function as transcription factors regulating the expression of genes. PPARs play essential roles in the regulation of cellular differentiation, development, and metabolism, and tumorigenesis of higher organisms.

<span class="mw-page-title-main">Lipoprotein lipase</span> Mammalian protein found in Homo sapiens

Lipoprotein lipase (LPL) (EC 3.1.1.34, systematic name triacylglycerol acylhydrolase (lipoprotein-dependent)) is a member of the lipase gene family, which includes pancreatic lipase, hepatic lipase, and endothelial lipase. It is a water-soluble enzyme that hydrolyzes triglycerides in lipoproteins, such as those found in chylomicrons and very low-density lipoproteins (VLDL), into two free fatty acids and one monoacylglycerol molecule:

<span class="mw-page-title-main">Mothers against decapentaplegic homolog 3</span> Protein-coding gene in humans

Mothers against decapentaplegic homolog 3 also known as SMAD family member 3 or SMAD3 is a protein that in humans is encoded by the SMAD3 gene.

<span class="mw-page-title-main">Angiopoietin</span> Protein family

Angiopoietin is part of a family of vascular growth factors that play a role in embryonic and postnatal angiogenesis. Angiopoietin signaling most directly corresponds with angiogenesis, the process by which new arteries and veins form from preexisting blood vessels. Angiogenesis proceeds through sprouting, endothelial cell migration, proliferation, and vessel destabilization and stabilization. They are responsible for assembling and disassembling the endothelial lining of blood vessels. Angiopoietin cytokines are involved with controlling microvascular permeability, vasodilation, and vasoconstriction by signaling smooth muscle cells surrounding vessels. There are now four identified angiopoietins: ANGPT1, ANGPT2, ANGPTL3, ANGPT4.

The ERRs are orphan nuclear receptors, meaning the identity of their endogenous ligand has yet to be unambiguously determined. They are named because of sequence homology with estrogen receptors, but do not appear to bind estrogens or other tested steroid hormones.

<span class="mw-page-title-main">Fatty acid-binding protein</span>

The fatty-acid-binding proteins (FABPs) are a family of transport proteins for fatty acids and other lipophilic substances such as eicosanoids and retinoids. These proteins are thought to facilitate the transfer of fatty acids between extra- and intracellular membranes. Some family members are also believed to transport lipophilic molecules from outer cell membrane to certain intracellular receptors such as PPAR. The FABPs are intracellular carriers that “solubilize” the endocannabinoid anandamide (AEA), transporting AEA to the breakdown by FAAH, and compounds that bind to FABPs block AEA breakdown, raising its level. The cannabinoids are also discovered to bind human FABPs that function as intracellular carriers, as THC and CBD inhibit the cellular uptake and catabolism of AEA by targeting FABPs. Competition for FABPs may in part or wholly explain the increased circulating levels of endocannabinoids reported after consumption of cannabinoids. Levels of fatty-acid-binding protein have been shown to decline with ageing in the mouse brain, possibly contributing to age-associated decline in synaptic activity.

<span class="mw-page-title-main">Peroxisome proliferator-activated receptor gamma</span> Nuclear receptor protein found in humans

Peroxisome proliferator-activated receptor gamma, also known as the glitazone reverse insulin resistance receptor, or NR1C3 is a type II nuclear receptor functioning as a transcription factor that in humans is encoded by the PPARG gene.

<span class="mw-page-title-main">Peroxisome proliferator-activated receptor alpha</span> Nuclear receptor protein found in humans

Peroxisome proliferator-activated receptor alpha (PPAR-α), also known as NR1C1, is a nuclear receptor protein functioning as a transcription factor that in humans is encoded by the PPARA gene. Together with peroxisome proliferator-activated receptor delta and peroxisome proliferator-activated receptor gamma, PPAR-alpha is part of the subfamily of peroxisome proliferator-activated receptors. It was the first member of the PPAR family to be cloned in 1990 by Stephen Green and has been identified as the nuclear receptor for a diverse class of rodent hepatocarcinogens that causes proliferation of peroxisomes.

<span class="mw-page-title-main">Liver X receptor alpha</span> Protein-coding gene in the species Homo sapiens

Liver X receptor alpha (LXR-alpha) is a nuclear receptor protein that in humans is encoded by the NR1H3 gene.

<span class="mw-page-title-main">Peroxisome proliferator-activated receptor delta</span> Nuclear receptor protein found in humans

Peroxisome proliferator-activated receptor delta(PPAR-delta), or (PPAR-beta), also known as Nuclear hormone receptor 1(NUC1) is a nuclear receptor that in humans is encoded by the PPARD gene.

<span class="mw-page-title-main">Estrogen-related receptor alpha</span> Protein-coding gene in the species Homo sapiens

Estrogen-related receptor alpha (ERRα), also known as NR3B1, is a nuclear receptor that in humans is encoded by the ESRRA gene. ERRα was originally cloned by DNA sequence homology to the estrogen receptor alpha, but subsequent ligand binding and reporter-gene transfection experiments demonstrated that estrogens did not regulate ERRα. Currently, ERRα is considered an orphan nuclear receptor.

<span class="mw-page-title-main">Integrin beta 6</span> Protein-coding gene in the species Homo sapiens

Integrin beta-6 is a protein that in humans is encoded by the ITGB6 gene. It is the β6 subunit of the integrin αvβ6. Integrins are αβ heterodimeric glycoproteins which span the cell’s membrane, integrating the outside and inside of the cell. Integrins bind to specific extracellular proteins in the extracellular matrix or on other cells and subsequently transduce signals intracellularly to affect cell behaviour. One α and one β subunit associate non-covalently to form 24 unique integrins found in mammals. While some β integrin subunits partner with multiple α subunits, β6 associates exclusively with the αv subunit. Thus, the function of ITGB6 is entirely associated with the integrin αvβ6.

<span class="mw-page-title-main">PPARGC1B</span> Protein-coding gene in the species Homo sapiens

Peroxisome proliferator-activated receptor gamma coactivator 1-beta is a protein that in humans is encoded by the PPARGC1B gene.

<span class="mw-page-title-main">PRDM16</span> Protein-coding gene in the species Homo sapiens

PR domain containing 16, also known as PRDM16, is a protein which in humans is encoded by the PRDM16 gene.

<span class="mw-page-title-main">ANGPTL3</span> Protein-coding gene in the species Homo sapiens

Angiopoietin-like 3, also known as ANGPTL3, is a protein that in humans is encoded by the ANGPTL3 gene.

<span class="mw-page-title-main">FNDC5</span>

Fibronectin type III domain-containing protein 5, the precursor of irisin, is a type I transmembrane glycoprotein that is encoded by the FNDC5 gene. Irisin is a cleaved version of FNDC5, named after the Greek messenger goddess Iris.

<span class="mw-page-title-main">Pirinixic acid</span> Chemical compound

Pirinixic acid is a peroxisome proliferator-activated receptor alpha (PPARα) agonist that is under experimental investigation for prevention of severe cardiac dysfunction, cardiomyopathy and heart failure as a result of lipid accumulation within cardiac myocytes. Treatment is primarily aimed at individuals with an adipose triglyceride lipase (ATGL) enzyme deficiency or mutation because of the essential PPAR protein interactions with free fatty acid monomers derived from the ATGL catalyzed lipid oxidation reaction. It was discovered as WY-14,643 in 1974.

<span class="mw-page-title-main">ANGPTL8</span> Mammalian protein found in Homo sapiens

ANGPTL8 is a protein that in humans is encoded by the C19orf80 gene.

Hypoxia inducible lipid droplet-associated is a protein that in humans is encoded by the HILPDA gene.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000167772 - Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000002289 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. Kim I, Kim HG, Kim H, Kim HH, Park SK, Uhm CS, et al. (March 2000). "Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis". The Biochemical Journal. 346 (Pt 3): 603–10. doi:10.1042/0264-6021:3460603. PMC   1220891 . PMID   10698685.
  6. Yoon JC, Chickering TW, Rosen ED, Dussault B, Qin Y, Soukas A, et al. (July 2000). "Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation". Molecular and Cellular Biology. 20 (14): 5343–9. doi:10.1128/MCB.20.14.5343-5349.2000. PMC   85983 . PMID   10866690.
  7. Kersten S, Mandard S, Tan NS, Escher P, Metzger D, Chambon P, et al. (September 2000). "Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene" (PDF). The Journal of Biological Chemistry. 275 (37): 28488–93. doi: 10.1074/jbc.M004029200 . PMID   10862772.
  8. 1 2 Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, Massagué J (April 2008). "TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4". Cell. 133 (1): 66–77. doi:10.1016/j.cell.2008.01.046. PMC   2390892 . PMID   18394990.
  9. 1 2 Kim SH, Park YY, Kim SW, Lee JS, Wang D, DuBois RN (November 2011). "ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression". Cancer Research. 71 (22): 7010–20. doi:10.1158/0008-5472.CAN-11-1262. PMC   3217078 . PMID   21937683.
  10. 1 2 Adhikary T, Brandt DT, Kaddatz K, Stockert J, Naruhn S, Meissner W, et al. (October 2013). "Inverse PPARβ/δ agonists suppress oncogenic signaling to the ANGPTL4 gene and inhibit cancer cell invasion". Oncogene. 32 (44): 5241–52. doi:10.1038/onc.2012.549. PMC   3938163 . PMID   23208498.
  11. 1 2 Zhu P, Goh YY, Chin HF, Kersten S, Tan NS (June 2012). "Angiopoietin-like 4: a decade of research". Bioscience Reports. 32 (3): 211–9. doi:10.1042/BSR20110102. hdl: 10356/94662 . PMID   22458843.
  12. Desai U, Lee EC, Chung K, Gao C, Gay J, Key B, et al. (July 2007). "Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice". Proceedings of the National Academy of Sciences of the United States of America. 104 (28): 11766–71. Bibcode:2007PNAS..10411766D. doi: 10.1073/pnas.0705041104 . PMC   1913890 . PMID   17609370.
  13. 1 2 Zhu P, Tan MJ, Huang RL, Tan CK, Chong HC, Pal M, et al. (March 2011). "Angiopoietin-like 4 protein elevates the prosurvival intracellular O2(-):H2O2 ratio and confers anoikis resistance to tumors". Cancer Cell. 19 (3): 401–15. doi: 10.1016/j.ccr.2011.01.018 . hdl: 10220/8177 . PMID   21397862.
  14. Tan MJ, Teo Z, Sng MK, Zhu P, Tan NS (June 2012). "Emerging roles of angiopoietin-like 4 in human cancer". Molecular Cancer Research. 10 (6): 677–88. doi: 10.1158/1541-7786.MCR-11-0519 . hdl: 10356/95626 . PMID   22661548.
  15. Huang RL, Teo Z, Chong HC, Zhu P, Tan MJ, Tan CK, et al. (October 2011). "ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VE-cadherin and claudin-5 clusters". Blood. 118 (14): 3990–4002. doi: 10.1182/blood-2011-01-328716 . PMID   21841165.
  16. Teo Z, Sng MK, Chan JS, Lim MM, Li Y, Li L, et al. (November 2017). "Elevation of adenylate energy charge by angiopoietin-like 4 enhances epithelial-mesenchymal transition by inducing 14-3-3γ expression". Oncogene. 36 (46): 6408–6419. doi:10.1038/onc.2017.244. PMC   5701092 . PMID   28745316.
  17. Tan ZW, Teo Z, Tan C, Choo CC, Loo WS, Song Y, et al. (October 2017). "ANGPTL4 T266M variant is associated with reduced cancer invasiveness". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1864 (10): 1525–1536. doi: 10.1016/j.bbamcr.2017.06.010 . hdl: 10220/44354 . PMID   28641978.
  18. Lim MM, Wee JW, Soong JC, Chua D, Tan WR, Lizwan M, et al. (October 2018). "Targeting metabolic flexibility via angiopoietin-like 4 protein sensitizes metastatic cancer cells to chemotherapy drugs". Molecular Cancer. 17 (1): 152. doi: 10.1186/s12943-018-0904-z . PMC   6195749 . PMID   30342537.
  19. Chong HC, Tan CK, Huang RL, Tan NS (Feb 2012). "Matricellular proteins: a sticky affair with cancers". Journal of Oncology. 2012: 351089. doi: 10.1155/2012/351089 . PMC   3306981 . PMID   22481923.
  20. Goh YY, Pal M, Chong HC, Zhu P, Tan MJ, Punugu L, et al. (December 2010). "Angiopoietin-like 4 interacts with integrins beta1 and beta5 to modulate keratinocyte migration". The American Journal of Pathology. 177 (6): 2791–803. doi:10.2353/ajpath.2010.100129. PMC   2993291 . PMID   20952587.
  21. Goh YY, Pal M, Chong HC, Zhu P, Tan MJ, Punugu L, et al. (October 2010). "Angiopoietin-like 4 interacts with matrix proteins to modulate wound healing". The Journal of Biological Chemistry. 285 (43): 32999–3009. doi: 10.1074/jbc.M110.108175 . PMC   2963335 . PMID   20729546.
  22. Chong HC, Chan JS, Goh CQ, Gounko NV, Luo B, Wang X, et al. (September 2014). "Angiopoietin-like 4 stimulates STAT3-mediated iNOS expression and enhances angiogenesis to accelerate wound healing in diabetic mice". Molecular Therapy. 22 (9): 1593–604. doi:10.1038/mt.2014.102. PMC   4435481 . PMID   24903577.
  23. Teo Z, Chan JS, Chong HC, Sng MK, Choo CC, Phua GZ, et al. (July 2017). "Angiopoietin-like 4 induces a β-catenin-mediated upregulation of ID3 in fibroblasts to reduce scar collagen expression". Scientific Reports. 7 (1): 6303. Bibcode:2017NatSR...7.6303T. doi:10.1038/s41598-017-05869-x. PMC   5524754 . PMID   28740178.
  24. Chen H, Lui YS, Tan ZW, Lee JY, Tan NS, Tan LP (May 2019). "Migration and Phenotype Control of Human Dermal Fibroblasts by Electrospun Fibrous Substrates". Advanced Healthcare Materials. 8 (9): e1801378. doi:10.1002/adhm.201801378. PMID   30901162. S2CID   85448471.
  25. Mousavizadeh R, Scott A, Lu A, Ardekani GS, Behzad H, Lundgreen K, et al. (June 2016). "Angiopoietin-like 4 promotes angiogenesis in the tendon and is increased in cyclically loaded tendon fibroblasts". The Journal of Physiology. 594 (11): 2971–83. doi:10.1113/JP271752. PMC   4887665 . PMID   26670924.
  26. Babapoor-Farrokhran S, Jee K, Puchner B, Hassan SJ, Xin X, Rodrigues M, et al. (June 2015). "Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy". Proceedings of the National Academy of Sciences of the United States of America. 112 (23): E3030-9. Bibcode:2015PNAS..112E3030B. doi: 10.1073/pnas.1423765112 . PMC   4466723 . PMID   26039997.
  27. Sukonina V, Lookene A, Olivecrona T, Olivecrona G (November 2006). "Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue". Proceedings of the National Academy of Sciences of the United States of America. 103 (46): 17450–5. Bibcode:2006PNAS..10317450S. doi: 10.1073/pnas.0604026103 . PMC   1859949 . PMID   17088546.
  28. Lafferty MJ, Bradford KC, Erie DA, Neher SB (October 2013). "Angiopoietin-like protein 4 inhibition of lipoprotein lipase: evidence for reversible complex formation". The Journal of Biological Chemistry. 288 (40): 28524–34. doi: 10.1074/jbc.M113.497602 . PMC   3789953 . PMID   23960078.
  29. Georgiadi A, Wang Y, Stienstra R, Tjeerdema N, Janssen A, Stalenhoef A, et al. (July 2013). "Overexpression of angiopoietin-like protein 4 protects against atherosclerosis development" (PDF). Arteriosclerosis, Thrombosis, and Vascular Biology. 33 (7): 1529–37. doi: 10.1161/ATVBAHA.113.301698 . PMID   23640487.
  30. Georgiadi A, Lichtenstein L, Degenhardt T, Boekschoten MV, van Bilsen M, Desvergne B, et al. (June 2010). "Induction of cardiac Angptl4 by dietary fatty acids is mediated by peroxisome proliferator-activated receptor beta/delta and protects against fatty acid-induced oxidative stress". Circulation Research. 106 (11): 1712–21. doi: 10.1161/CIRCRESAHA.110.217380 . PMID   20378851.
  31. Catoire M, Alex S, Paraskevopulos N, Mattijssen F, Evers-van Gogh I, Schaart G, et al. (March 2014). "Fatty acid-inducible ANGPTL4 governs lipid metabolic response to exercise". Proceedings of the National Academy of Sciences of the United States of America. 111 (11): E1043-52. Bibcode:2014PNAS..111E1043C. doi: 10.1073/pnas.1400889111 . PMC   3964070 . PMID   24591600.
  32. Xiao YL, Kash JC, Beres SB, Sheng ZM, Musser JM, Taubenberger JK (March 2013). "High-throughput RNA sequencing of a formalin-fixed, paraffin-embedded autopsy lung tissue sample from the 1918 influenza pandemic". The Journal of Pathology. 229 (4): 535–45. doi:10.1002/path.4145. PMC   3731037 . PMID   23180419.
  33. Li L, Chong HC, Ng SY, Kwok KW, Teo Z, Tan EH, et al. (February 2015). "Angiopoietin-like 4 Increases Pulmonary Tissue Leakiness and Damage during Influenza Pneumonia". Cell Reports. 10 (5): 654–663. doi: 10.1016/j.celrep.2015.01.011 . PMC   7185373 . PMID   25660016.
  34. Li L, Foo BJ, Kwok KW, Sakamoto N, Mukae H, Izumikawa K, et al. (June 2019). "Antibody Treatment against Angiopoietin-Like 4 Reduces Pulmonary Edema and Injury in Secondary Pneumococcal Pneumonia". mBio. 10 (3). doi:10.1128/mBio.02469-18. PMC   6550533 . PMID   31164474.

Further reading